Integrating Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanism of Astragaloside IV in Treating Bleomycin-Induced Pulmonary Fibrosis-Reference-Cited by-同舟云学术

Integrating Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanism of Astragaloside IV in Treating Bleomycin-Induced Pulmonary Fibrosis

Published:2023-04 Issue: Volume:Volume 17 Page:1289-1302
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Yuan Su,Zuo Biao,Zhou Si-Cong,Wang Meng,Tan Kai-Yue,Chen Zhi-Wei,Cao Wen-Fu

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference41 articles.

1. Natural history of idiopathic pulmonary fibrosis

2. The Therapeutic Mechanism of Schisandrol A and Its Metabolites on Pulmonary Fibrosis Based on Plasma Metabonomics and Network Analysis

3. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?

4. Editorial: Pulmonary fibrosis: One manifestation, various diseases

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Astragaloside IV inhibits inflammation caused by influenza virus via reactive oxygen species/NOD‐like receptor thermal protein domain associated protein 3/Caspase‐1 signaling pathway;Immunity, Inflammation and Disease;2024-06

2. Insights into the potential dual-antibacterial mechanism of Kelisha capsule on Escherichia coli;BMC Complementary Medicine and Therapies;2024-05-28

3. Tanshinone IIA alleviates pulmonary fibrosis by modulating glutamine metabolic reprogramming based on [U-13C5]-glutamine metabolic flux analysis;Journal of Advanced Research;2024-05

4. The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis;Stem Cells and Cloning: Advances and Applications;2023-09